Chemocentryx Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CHEMOCENTRYX, and when can generic versions of CHEMOCENTRYX drugs launch?
CHEMOCENTRYX has one approved drug.
There are four US patents protecting CHEMOCENTRYX drugs.
There are ninety patent family members on CHEMOCENTRYX drugs in thirty-seven countries and ten supplementary protection certificates in ten countries.
Summary for Chemocentryx
| International Patents: | 90 |
| US Patents: | 4 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Chemocentryx
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chemocentryx | TAVNEOS | avacopan | CAPSULE;ORAL | 214487-001 | Oct 7, 2021 | RX | Yes | Yes | 8,445,515 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Chemocentryx | TAVNEOS | avacopan | CAPSULE;ORAL | 214487-001 | Oct 7, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| Chemocentryx | TAVNEOS | avacopan | CAPSULE;ORAL | 214487-001 | Oct 7, 2021 | RX | Yes | Yes | 11,951,214 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Chemocentryx | TAVNEOS | avacopan | CAPSULE;ORAL | 214487-001 | Oct 7, 2021 | RX | Yes | Yes | 8,906,938 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Chemocentryx | TAVNEOS | avacopan | CAPSULE;ORAL | 214487-001 | Oct 7, 2021 | RX | Yes | Yes | 11,603,356 | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Chemocentryx | TAVNEOS | avacopan | CAPSULE;ORAL | 214487-001 | Oct 7, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Chemocentryx Drugs
Supplementary Protection Certificates for Chemocentryx Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2381778 | LUC00258 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: AVACOPAN ET LES SELS PHARMACEUTIQUEMENT ACCEPTABLES QUI EN DERIVENT; AUTHORISATION NUMBER AND DATE: EU/1/21/1605 20220119 |
| 2381778 | C202230016 | Spain | ⤷ Sign Up | PRODUCT NAME: AVACOPAN Y SALES FARMACEUTICAMENTE ACEPTABLES DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/21/1605; DATE OF AUTHORISATION: 20220111; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/21/1605; DATE OF FIRST AUTHORISATION IN EEA: 20220111 |
| 2381778 | 122022000029 | Germany | ⤷ Sign Up | PRODUCT NAME: AVACOPAN; REGISTRATION NO/DATE: EU/1/21/1605 20220111 |
| 3508477 | PA2022006 | Lithuania | ⤷ Sign Up | PRODUCT NAME: AVAKOPANAS IR JO FARMACINIU POZIURIU PRIIMTINOS DRUSKOS ; REGISTRATION NO/DATE: EU/1/21/1605 20220111 |
| 2381778 | 22C1020 | France | ⤷ Sign Up | PRODUCT NAME: AVACOPAN ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/21/1605 20220119 |
| 2381778 | 2022C/518 | Belgium | ⤷ Sign Up | PRODUCT NAME: TAVNEOS - AVACOPAN ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/21/1605 20220119 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
